Enhancing GABA's ability to modulate immune responses
AssigneeThe Regents of the University of California
InventorsDaniel Kaufman, Jide Tian
Life of this patent
Estimating the term…
Abstract
Embodiments methods of reducing an inflammatory immune response (e.g., inhibiting a Th1 response) and/or promoting a regulatory immune response (e.g., enhancing Treg(s)) in a mammal are provided where the method methods involve administering to the mammal a GABAA receptor positive allosteric modulator (PAM) in an amount sufficient to reduce an inflammatory immune response and/or to promote a regulatory immune response said mammal. In certain embodiments the PAM is administered in conjunction with a GABA receptor activating ligand (e.g., GABA).
Claims15
A method of reducing an inflammatory immune response and/or promoting a regulatory immune response in a mammal, said method comprising administering to said mammal the GABAA receptor positive allosteric modulator (PAM) alprazolam and the GABA receptor activating ligand GABA, wherein the dose of GABA would be sufficient to achieve a reduction of an inflammatory immune response and/or promotion of a regulatory immune response when used alone, and the dose of alprazolam is sufficient to increase the reduction of an inflammatory immune response and/or promotion of a regulatory immune response, and wherein the combination of said alprazolam and GABA is more effective to reduce an inflammatory immune response and/or to promote a regulatory immune response in said mammal than when either agent is administered alone.
Dependencies are inferred from the claim text.